AIFA – PRALUENT (alirocumab): il registro di monitoraggio è aggiornato e convertito in piano terapeutico web-based
14/03/2024
Leggi
AIFA – Classe di rimborsabilita’ A: formulazione mensile PRALUENT (alirocumab) 300 mg soluzione iniettabile in penna pre-riempita (1 penna) e 300 mg soluzione iniettabile in penna pre-riempita (3 penne)
14/03/2024
Leggi
AIFA – Repatha (evolocumab): il registro di monitoraggio è aggiornato e convertito in piano terapeutico web-based
14/03/2024
Leggi
Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model
Helmink MAG, Hageman SHJ, Eliasson B, et al.
Diabetes Obes Metab. Pub. online 8 Mar 2024.
Leggi
The association between previous use of anti-obesity medication and semaglutide weight loss outcomes
Ghusn W, Fansa S, Anazco D, et al.
Diabetes Obes Metab. Pub. online 12 Mar 2024.
Leggi
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
Brown DM, Boyer DS, Do DV, et al.
Lancet. 2024;S0140-6736(23)02577-1.
Leggi
Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada)
Jain AB, Reichert SM, Amadid H, et al.
Diabetes Obes Metab. Pub. online 11 Mar 2024.
Leggi
Hydrogel dressings for diabetic foot ulcer: A systematic review and meta-analysis
Zhao H, Wu Y, Xie Y, et al.
Diabetes Obes Metab. Pub. online 11 Mar 2024.
Leggi
Development of machine learning models for the identification of elevated ketone bodies during hyperglycemia in patients with type 1 diabetes
Cichosz SL, Bender C
Diabetes Technol Ther. Pub. online 8 Mar 2024.
Leggi
Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis
Cao L, An Y, Liu H, et al.
BMC Med. 2024;22(1):101.
Leggi